VEGFA and ischemia: Second, it flags low-probability responders (<40%) who might benefit from treatment augmentation—such as earlier transition to faricimab (VEGF-angiopoietin-2 [Ang]2 inhibitor) in high-ischemia cases (38), or continuous glucose monitoring (CGM)-guided glycemic control for high-variability patients (39).